Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplant Tolerance Clear all
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

NCT00497926
View directory record Official record
Conditions
Kidney Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

Associating Renal Transplantation With the ITN Signature of Tolerance

NCT01516177
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants

NCT00001858
View directory record Official record
Conditions
Graft Rejection, Kidney Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
View directory record Official record
Conditions
Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions
Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

NCT00407160
View directory record Official record
Conditions
Kidney Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571
View directory record Official record
Conditions
Diabetes
Interventions
Human Pancreatic Islet Transplantation
Biological
Lead sponsor
Midhat H. Abdulreda
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

NCT00063817
View directory record Official record
Conditions
End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions
Conditioning Regimen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

NCT03995901
View directory record Official record
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MDR-101
Biological
Lead sponsor
Medeor Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation

NCT00001857
View directory record Official record
Conditions
Kidney Transplantation
Interventions
BG9588
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Results available

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

NCT00320606
View directory record Official record
Conditions
Liver Transplant, Liver Transplantation
Interventions
Immunosuppression Withdrawal
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

Study of Tolerant Kidney Transplant Recipients

NCT01338779
View directory record Official record
Conditions
Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant, Transplant Tolerance
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Prospective L-arginine Study

NCT01485757
View directory record Official record
Conditions
Heart Transplant
Interventions
L-arginine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jul 21, 2026, 9:30 PM EDT
Not listed Early Phase 1 Interventional

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

NCT03292445
View directory record Official record
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074
View directory record Official record
Conditions
Multiple Myeloma
Interventions
elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

NCT02525029
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pregnyl®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 76 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Not listed Phase 1Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

NCT00498160
View directory record Official record
Conditions
Renal Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

NCT00183248
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease, Kidney Failure
Interventions
Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Jul 21, 2026, 9:30 PM EDT